The Week

Ascendis Pharmac (ASND.US) rose 9.14% this week to close at $270.56, against a 0.09% gain for the S&P 500 — outperforming the benchmark by about 9.05 percentage points. The stock gapped higher on Monday and ran to $268.98 before pulling back to $260.25 on Tuesday. It then recovered over the next three sessions, touching a weekly high of $272.44 on Thursday before holding in a narrow range near those levels.

Key Events

The week’s central story was the global settlement and licence agreement between Ascendis and BioMarin over YUVIWEL® (Navepegritide). On Monday the two companies announced a binding term sheet ending their global patent disputes, with Ascendis set to pay royalties to BioMarin on Yuviwel sales in the US, EU, Brazil and South Korea. With the legal overhang removed, investor attention shifted back to Yorvipath-driven growth. Director Lars Holtug disclosed a small sale of 236 shares on Friday, worth roughly $62,000. The transaction had limited bearing on the week’s broader narrative.

Analyst Ratings

Twenty brokers cover the stock: 16 rate it buy and 4 rate it overweight, with no hold, underweight or sell ratings. The consensus recommendation is strong buy, and the consensus target price sits at $313.68, about 15.9% above spot. Individual targets range from $269.31 to $361.50, a gap of around $92 that points to meaningful dispersion in views, though even the low end stands above the week’s close. Within biotechnology, the stock ranks 24th out of 507 names, placing it in the top 5% of the industry.

The Week Ahead

The macro calendar picks up next week. The NFIB small business optimism index lands on Tuesday 8 September, followed on Thursday 10 September by initial jobless claims, PPI-related figures and existing home sales. Ascendis has no earnings date of its own on the horizon, so the near-term focus stays on how the settlement terms are absorbed and how the market reprices the pace of Yorvipath growth.

In Short

This week carried a clear tension: the patent settlement removed legal uncertainty and the consensus sits at strong buy with a target above spot, yet the wide target range reflects divided views on the royalty burden versus growth elasticity. What matters next is whether Yorvipath sales momentum holds within the settlement framework, and whether the macro prints trigger rotation out of biotechnology.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.